A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients

@article{Francis2015AST,
  title={A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients},
  author={Jose Francis and Biswajit Dubashi and Rajan Sundaram and Suresh Chandra Pradhan and Adithan Chandrasekaran},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2015},
  volume={76},
  pages={1185-1189}
}
Imatinib mesylate is presently the first-line treatment for chronic myeloid leukemia (CML). Therapeutic drug monitoring (TDM) and pharmacogenetic screening is warranted for better management of imatinib therapy. The present study was framed to explore the influence of common drug transporter gene polymorphisms of ABCB1, ABCG2, OCT1 and trough level concentration on commonly occurring adverse events in CML patients treated with imatinib mesylate. A total number of 111 patients in chronic phase… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
4 Citations
32 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Adverse drug reactions of imatinib therapy in chronic myeloid leukemia patients: a single-center surveillance study

  • J Francis, M Palaniappan, B Dubashi, SC Pradhan, C Adithan
  • J Pharmacol Pharmacother
  • 2015
1 Excerpt

A simple and rapid method for the quantification of Imatinib mesylate and desmethyl imatinib in human Plasma using LC–MS/MS and its application to routine Therapeutic drug monitoring

  • J Francis, B Dubashi, R Sundaram
  • World J Pharma Res
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…